Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04408430
Other study ID # 20-002438
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 8, 2021
Est. completion date December 2024

Study information

Verified date April 2024
Source Mayo Clinic
Contact Tatiana Kaptzan, Ph. D.
Phone 507-284-1610
Email kaptzan.tatiana@mayo.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective multicenter study enrolling high surgical risk patients with severe mitral annular calcification (MAC) and symptomatic mitral valve dysfunction (severe stenosis, ≥ moderate to severe regurgitation, or mixed ≥ moderate stenosis and ≥ regurgitation). There are 2 Arms in this study: 1) "Transseptal (TS) Valve-in-MAC" (ViMAC) Arm, and 2) Natural History of Disease Registry (NHDR) for patients treated with medical treatment only (which includes patients who meet inclusion criteria but can't be treated with transeptal ViMAC due to the presence of anatomical exclusion criteria or other exclusion criteria) and have not had other procedures that may impact outcomes (i.e., alcohol septal ablation or radiofrequency ablation). The study also includes a Registry of Permanently Unassigned" for subjects who undergo preemptive septal ablation procedures (alcohol or radiofrequency) in anticipation of continuing onto ViMAC arm, but are not accepted in the ViMAC Study arm or the patient chooses not to undergo ViMAC procedure.


Description:

STUDY OBJECTIVE The purpose of this study is to establish the safety and effectiveness of the Edwards SAPIEN 3, SAPIEN 3 Ultra and SAPIEN 3 Ultra RESILIA (SAPIEN 3/Ultra/RESILIA) valves with Commander delivery system in patients with severe mitral annular calcification and symptomatic mitral valve dysfunction who are not candidates for standard mitral valve surgery. STUDY DESIGN A prospective multicenter study enrolling high surgical risk patients with severe mitral annular calcification (MAC) and symptomatic mitral valve dysfunction (severe stenosis, ≥ moderate to severe regurgitation, or mixed ≥ moderate stenosis and ≥ regurgitation). There are 2 arms in this study: 1) "Transseptal (TS) Valve-in-MAC (ViMAC)" arm, 2) Natural History of Disease Registry (NHDR). Patients treated with medical treatment only (which will include patients who meet inclusion criteria but can't be treated with transseptal ViMAC due to the presence of anatomical exclusion criteria or other exclusion criteria) and have not had other procedures that may impact outcomes (i.e. alcohol septal ablation, radiofrequency ablation). Enrollment Enrollment will consist of 110 patients in the treatment arm (transseptal ViMAC) and up to 100 in the medically treated arm).


Recruitment information / eligibility

Status Recruiting
Enrollment 210
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: All Candidates must meet the following criteria: 1. - 18 years of age or older 2. -Severe mitral annular calcification with symptomatic mitral valve dysfunction including severe mitral stenosis defined as mitral valve area (MVA) of =1.5 cm2, or = moderate to severe mitral regurgitation, or mixed = moderated stenosis and = moderate regurgitation. For this study, the severity of mitral regurgitation will be graded according to the 2017 American Society of Echocardiography Guidelines: None, Trivial, Mild 1(+), Moderate 2(+), Moderate to severe 3(+), and severe 4(+). 3. - NYHA Functional Class =II. 4. The heart team agrees that valve implantation will likely benefit the patient. 5. High or prohibitive risk for standard mitral valve surgery as determined by the heart team (at least one site cardiac surgeon must personally examine the subject to determine operative risk in patients presented for inclusion to ViMAC arm). NOTE: Patients not interested in mitral intervention or who are being considered for inclusion in the Natural History of Disease Registry are not required to be evaluated in person by a surgeon.) 6. The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site. 7. The study patient agrees to comply with all required post-procedure follow-up visits including annual visits through 5 years. Exclusion Criteria for ViMAC subjects (does not apply to the Natural History of Disease Registry): 1. - The heart team considers the patient is a surgical candidate. 2. - Mitral annulus is not severely calcified. 3. - Myocardial infarction requiring revascularization within 30 days from procedure. 4. - Clinically significant untreated coronary artery disease requiring revascularization. 5. Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days of the index procedure (unless part of planned strategy for treatment of concomitant coronary artery disease). Implantation of a permanent pacemaker is not exclusionary. 6. Any patient with a balloon valvuloplasty (BMV) within 30 days of the procedure (unless BMV is a bridge to ViMAC procedure after a qualifying Echo). 7. Severe symptomatic tricuspid regurgitation (hepatic dysfunction, ascites, edema not controlled with diuretics) requiring surgery. 8. Leukopenia (WBC < 3000 cell/mL), acute anemia (Hgb < 9 g/dL), Thrombocytopenia (Platelets < 50,000 cell/mL), history of coagulopathy or hypercoagulable state. 9. Hypertrophic obstructive cardiomyopathy (HOCM) with mean LVOT gradient of =20 mm Hg at rest or =50 mmHg with Valsalva. 10. Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation or mechanical heart assistance within 30 days of screening evaluation. 11. Need for emergency surgery for any reason. 12. Severe left ventricular dysfunction with LVEF < 20%. 13. Echocardiographic evidence of intracardiac mass, thrombus or vegetation. 14. Active upper GI bleeding within 90 days prior to procedure. 15. A known contraindication or hypersensitivity to all anticoagulation regimens, or inability to be anticoagulated for the study procedure. 16. Cardiac anatomy that would preclude appropriate delivery and deployment of an Edwards SAPIEN 3/Ultra/RESILIA valve in MAC via transseptal access, including but not limited to: - Native neo mitral annulus size < 275 mm2 or > 810 mm2 as measured by CT scan. - Significant risk of LVOT obstruction or valve embolization as assessed by CT core lab 17. Clinically (by neurologist) or neuroimaging confirmed stroke or transient ischemic attack (TIA) within 90 days of the procedure. 18. Estimated life expectancy <12 months due to non-cardiac conditions. 19. Expectation that patient will not improve despite treatment of mitral valve dysfunction. 20. Active bacterial endocarditis within 180 days of procedure. 21. - Severe right ventricular dysfunction as assessed by Echo core lab 22. - Active infection requiring antibiotic therapy (subject may be a candidate after 2 weeks of antibiotic discontinuation. 23. - Female who is pregnant or lactating. 24. - Participating in another investigational device study. 25. - Aortic valve disease requiring intervention. If aortic valve intervention is required, the AVR procedure should be performed first and if the patient remains symptomatic after AVR, may be presented for consideration for inclusion in this trial. 26. - Severe fixed pulmonary hypertension (PASP =70 mmHg and more than 2/3 of the systemic systolic blood pressure). 27. - Severe chronic obstructive pulmonary disease requiring continuous home oxygen. 28. - The patient refuses mitral valve intervention 29. - Recent symptomatic COVID-19 infection with residual symptoms that may affect the outcomes of this trial.

Study Design


Intervention

Device:
Transseptal ViMAC
Transseptal TMVR using balloon-expandable aortic transcatheter valves.

Locations

Country Name City State
United States Piedmont Healthcare Atlanta Georgia
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Brigham and Women's Hospital Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts
United States Sutter Health Burlingame California
United States Northwestern University Medical School Chicago Illinois
United States Henry Ford Health System Detroit Michigan
United States Uchealth Heart & Vascular Clinic Harmony Campus Fort Collins Colorado
United States Cedars-Sinai Medical Center Los Angeles California
United States Intermountain Medical Center Murray Utah
United States Columbia University Medical Center/NYPH New York New York
United States The Sentara Heart Valve and Structural Disease Center Norfolk Virginia
United States Banner - University Medicine Cardiology Clinic Phoenix Arizona
United States Baylor Scott and White - The Heart Hospital - Plano Plano Texas
United States Oregon Health & Science University Portland Oregon
United States Mayo Clinic Rochester Minnesota
United States University of Texas Health Science Center at San Antonio San Antonio Texas
United States Pima Heart & Vascular Tucson Arizona
United States Oklahoma Heart Institute Utica Office Tulsa Oklahoma
United States Medstar Washington Hospital Center Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Mayra Guerrero

Country where clinical trial is conducted

United States, 

References & Publications (6)

Guerrero M, Greenbaum A, O'Neill W. First in human percutaneous implantation of a balloon expandable transcatheter heart valve in a severely stenosed native mitral valve. Catheter Cardiovasc Interv. 2014 Jun 1;83(7):E287-91. doi: 10.1002/ccd.25441. Epub 2014 Mar 14. — View Citation

Guerrero M, Urena M, Himbert D, Wang DD, Eleid M, Kodali S, George I, Chakravarty T, Mathur M, Holzhey D, Pershad A, Fang HK, O'Hair D, Jones N, Mahadevan VS, Dumonteil N, Rodes-Cabau J, Piazza N, Ferrari E, Ciaburri D, Nejjari M, DeLago A, Sorajja P, Zah — View Citation

Guerrero M, Urena M, Pursnani A, Wang DD, Vahanian A, O'Neill W, Feldman T, Himbert D. Balloon expandable transcatheter heart valves for native mitral valve disease with severe mitral annular calcification. J Cardiovasc Surg (Torino). 2016 Jun;57(3):401-9. — View Citation

Guerrero M, Wang DD, Himbert D, Urena M, Pursnani A, Kaddissi G, Iyer V, Salinger M, Chakravarty T, Greenbaum A, Makkar R, Vahanian A, Feldman T, O'Neill W. Short-term results of alcohol septal ablation as a bail-out strategy to treat severe left ventricular outflow tract obstruction after transcatheter mitral valve replacement in patients with severe mitral annular calcification. Catheter Cardiovasc Interv. 2017 Dec 1;90(7):1220-1226. doi: 10.1002/ccd.26975. Epub 2017 Mar 7. — View Citation

Guerrero M, Wang DD, O'Neill W. Percutaneous alcohol septal ablation to acutely reduce left ventricular outflow tract obstruction induced by transcatheter mitral valve replacement. Catheter Cardiovasc Interv. 2016 Nov 15;88(6):E191-E197. doi: 10.1002/ccd.26649. Epub 2016 Jul 5. — View Citation

Russell HM, Guerrero ME, Salinger MH, Manzuk MA, Pursnani AK, Wang D, Nemeh H, Sakhuja R, Melnitchouk S, Pershad A, Fang HK, Said SM, Kauten J, Tang GHL, Aldea G, Feldman TE, Bapat VN, George IM. Open Atrial Transcatheter Mitral Valve Replacement in Patients With Mitral Annular Calcification. J Am Coll Cardiol. 2018 Sep 25;72(13):1437-1448. doi: 10.1016/j.jacc.2018.07.033. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Additional Endpoint: Technical Success • Technical success at exit from the cath lab.
Defined as:
Successful vascular access, delivery and retrieval of the transcatheter valve delivery system.
Deployment of a single valve.
Correct position of transcatheter valve in the mitral annulus.
Adequate performance of the prosthetic heart valve (MVA > 1.5 cm2) without residual mitral regurgitation grade =2 (+).
No need for additional surgery or re-intervention (includes drainage of pericardial effusion).
The patient leaves the cath lab alive.
Immediately after the intervention procedure.
Other Additional Endpoint: Procedural Success • Procedural Success at 30 days.
Defined as:
Device success at 30 days.
No device/procedure related SAE's including: death, stroke, MI or coronary ischemia requiring PCI or CABG, stage 2 or 3 AKI including dialysis, life threatening bleeding, major vascular or access complications (arterial, venous, or TA - any event requiring additional unplanned surgical or transcatheter intervention), pericardial effusion or tamponade requiring drainage, severe hypotension, heart failure or respiratory failure requiring intravenous pressors or invasive or mechanical treatments such as ultrafiltration or hemodynamic assist devices including intra-aortic balloon pump or left ventricular assist device, or prolonged intubation for =48 hrs, or any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention.
30 days
Other Additional Endpoint: Device Success Device success is defined as:
Stroke free survival with original valve in place.
No need for additional surgery or re-intervention related to the procedure, access or to the replacement valve.
Proper placement and intended function of the replacement valve, including
No migration, fracture, thrombosis, hemolysis or endocarditis.
No replacement valve stenosis (MV gradient < 10 mmHg).
Replacement valve regurgitation < 2 + (including central and paravalvular leak) and without associated hemolysis.
No increase in AI from baseline (more than 1 grade) and LVOT gradient < 20 mmHg increase from baseline.
30 days.
Other Additional Efficacy Endpoint - NYHA Class at 30 days. • Change from baseline in NYHA Class at 30 days. 30 days.
Other Additional Efficacy Endpoint - Distance walked in 6 MWT at 30 days • Change from baseline in distance walked measure by the 6 MWT at 30 days. 30 days.
Other Additional Efficacy Endpoint - KCCQ at 30 days • Change from baseline in KCCQ at 30 days. 30 days.
Other Additional Efficacy Endpoint - MR severity at 30 days • Degree of mitral regurgitation (central and paravalvular) at 30 days. 30 days
Other Additional Safety Endpoint - Stroke at 30 days and 1 year. • Stroke at 30 days and 1 year. 30 days and 1 year.
Other Additional Safety Endpoint - Need for ASD Closure • Iatrogenic ASD causing RV failure or hypoxemia or need for ASD closure at discharge and 30 days. 30 days.
Other Additional Safety Endpoint - New LVOT Gradient • New mean LVOT gradient = 20 mmHg, or = 20 mmHg increase from baseline LVOT gradient at 30 days and 1 year. 30 days and 1 year.
Other Additional Efficacy Endpoint - Mitral Valve Reintervention • Mitral Valve reintervention at 30 days and 1 year. 30 days and 1 year.
Other Additional Safety Endpoint - Hospitalizations at 1 year • Number of hospitalizations at 1 year. 1 year.
Other Additional Efficacy Endpoint - Days Alive Out of the Hospital • Days alive out of hospital at 1 year from index procedure (ViMAC arm) or from assignment day (Natural History Registry). 1 year.
Other Additional Safety Endpoint - Hemolysis • Hemolysis at 30 days and 1 year. 30 days and 1 year.
Other Additional Safety Endpoint - Endocarditis • Endocarditis at 30 days and 1 year. 30 days and 1 year.
Other Additional Safety Endpoint - Blood Transfusion • Blood transfusion at 30 days and 1 year. 30 days and 1 year.
Other Additional Safety Endpoint - New Pacemaker Requirement • New pacemaker requirement at 30 days and 1 year. 30 days and 1 year.
Other Additional Safety Endpoint - New Aortic Valve Insufficiency • New aortic valve insufficiency at 30 days and 1 year. 30 days and 1 year.
Other Additional Safety Endpoint - Acute Kidney Injury • Acute kidney injury (MVARC) at 30 days and 1 year. 30 days and 1 year.
Primary Primary Safety Endpoint: All Cause Morality and Hospitalization for Heart Failure A non-hierarchical composite of all-cause mortality and hospitalization for heart failure. 1 year.
Secondary Secondary Effectiveness Endpoint • Stroke at 30 days and 1 year. 1 year
Secondary Secondary Effectiveness Endpoint • Change from baseline in New York Heart Association Class at 1 year. 1 year.
Secondary Secondary Effectiveness Endpoint • Change from baseline in distance walked measure by the 6 Minute Walk Test at 1 year. 1 year.
Secondary Secondary Effectiveness Endpoint • Change from baseline in quality-of-life measure by the Kansas City Cardiomyopathy Questionnaire (KCCQ) at 1 year. 1 year.
Secondary Secondary Effectiveness Endpoint • Echocardiographic assessment of degree of mitral regurgitation (central and paravalvular) at 1 year. 1 year.
Secondary Secondary Effectiveness Endpoint • Significant mitral stenosis defined as mean mitral valve gradient by echo > 10 mmHg at 1 year. 1 year.
See also
  Status Clinical Trial Phase
Completed NCT03278574 - Flexible Band vs Rigid Ring for Degenerative Mitral Valve Disease N/A
Suspended NCT04960280 - A Study to Evaluate a Computerized Stethoscope Called ©Voqx to Diagnose Heart Disease N/A
Recruiting NCT05021614 - Valveclip® Transcatheter Mitral Valve Repair Study N/A
Not yet recruiting NCT06167213 - ALLIANCE Mitral: Safety and Effectiveness of SAPIEN X4 Transcatheter Heart Valve - Mitral N/A
Not yet recruiting NCT06465745 - AltaValve Pivotal Trial N/A
Withdrawn NCT05040451 - Carillon Mitral Contour System for Treatment of Exercise Induced Functional Mitral Regurgitation
Withdrawn NCT03714412 - Feasibility Study of Patients With Severe MR Treated With the Cardiovalve TMVR System N/A
Recruiting NCT02592889 - (MitraClip in Non-Responders to Cardiac Resynchronization Therapy) Phase 4
Completed NCT02355418 - The Role of Myocardial Fibrosis in Degenerative Mitral Regurgitation
Completed NCT01841554 - Cardioband With Transfemoral Delivery System N/A
Not yet recruiting NCT01431222 - Abrogation of Mitral Regurgitation Using the MitraClip System in High-Risk Patients Unsuitable for Surgery Phase 4
Not yet recruiting NCT03870516 - Left Chamber Function in Mitral Regurgitation and Predicting Outcome After Replacement and Targeting for Early Surgery N/A
Active, not recruiting NCT03230747 - SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation N/A
Enrolling by invitation NCT04031274 - Transcatheter Treatment for Combined Aortic and Mitral Valve Disease. The Aortic+Mitral TRAnsCatheter (AMTRAC) Valve Registry
Completed NCT05836480 - Immediate Suboptimal Result of Mitral Valve Repair: Late Implications in a Matched Cohort Study
Completed NCT05836532 - Long Term Results of Surgical and Percutaneous Double Orefices Mitral Repair in Patient With p2 Prolapse Causing Degenerative Mitral Regurgitation
Completed NCT05850026 - Mitral Regurgitation in Hypertrophic Obstructive Cardiomyopathy: Fix it in a Simple, Effective and Durable Way!
Recruiting NCT03975998 - Dutch-AMR: Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Mitral Regurgitation
Completed NCT01162083 - Identifying an Ideal Cardiopulmonary Exercise Test Parameter N/A
Suspended NCT00787293 - Study of Safety and Efficacy of the Percutaneous Reduction of Mitral Valve Regurgitation in Heart Failure Patients Phase 2